Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

Rhea-AI Summary

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on July 28, 2022, at 5:00 PM ET to discuss its financial results and corporate updates for Q2 2022. The call will be available via live webcast on the company's website. Ultragenyx focuses on developing therapies for rare genetic diseases, boasting a portfolio of approved medicines and candidates for unmet medical needs. The company emphasizes efficient drug development to deliver timely therapies to patients.

Positive

• Ultragenyx has a diverse portfolio of approved medicines.
• The company targets serious rare and ultra-rare genetic diseases.
• Focus on time- and cost-efficient drug development.

Negative

• None.

NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, July 28, 2022, at 5:00pm ET to discuss its financial results and corporate update for the quarter ended June 30, 2022.

The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. To participate in the live call, please register by clicking on the following link (registration link), and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The replay of the call will be available for one year.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contacts
Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
415-475-6370

Media
Jeff Blake
415-612-7784
media@ultragenyx.com

 

FAQ

When will Ultragenyx announce its Q2 2022 financial results?

Ultragenyx will announce its Q2 2022 financial results on July 28, 2022, at 5:00 PM ET.

How can I participate in the Ultragenyx conference call?

To participate in the Ultragenyx conference call, register via the provided registration link and join the call on July 28, 2022.

What is the main focus of Ultragenyx Pharmaceutical?

Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases.